The α-emitter 211At labeled to a monoclonal antibody has proven safe and effective in treating microscopic ovarian cancer in the abdominal cavity of mice. Women in complete clinical remission after second-line chemotherapy for recurrent ovarian carcinoma were enrolled in a phase I study. The aim was to determine the pharmacokinetics for assessing absorbed dose to normal tissues and investigating toxicity. Methods: Nine patients underwent laparoscopy 2–5 d before the therapy; a peritoneal catheter was inserted, and the abdominal cavity was inspected to exclude the presence of macroscopic tumor growth or major adhesions. 211At was labeled to MX35 F(ab′)2 using the reagent N-succinimidyl-3-(trimethylstannyl)-benzoate. Patients were infused with 211At-MX35 F(ab′)2 (22.4–101 MBq/L) in dialysis solution via the peritoneal catheter. γ-camera scans were acquired on 3–5 occasions after infusion, and a SPECT scan was acquired at 6 h. Samples of blood, urine, and peritoneal fluid were collected at 1–48 h. Hematology and renal and thyroid function were followed for a median of 23 mo. Results: Pharmacokinetics and dosimetric results were related to the initial activity concentration (IC) of the infused solution. The decay-corrected activity concentration decreased with time in the peritoneal fluid to 50% IC at 24 h, increased in serum to 6% IC at 45 h, and increased in the thyroid to 127% ± 63% IC at 20 h without blocking and less than 20% IC with blocking. No other organ uptakes could be detected. The cumulative urinary excretion was 40 kBq/(MBq/L) at 24 h. The estimated absorbed dose to the peritoneum was 15.6 ± 1.0 mGy/(MBq/L), to red bone marrow it was 0.14 ± 0.04 mGy/(MBq/L), to the urinary bladder wall it was 0.77 ± 0.19 mGy/(MBq/L), to the unblocked thyroid it was 24.7 ± 11.1 mGy/(MBq/L), and to the blocked thyroid it was 1.4 ± 1.6 mGy/(MBq/L) (mean ± SD). No adverse effects were observed either subjectively or in laboratory parameters. Conclusion: This study indicates that by intraperitoneal administration of 211At-MX35 F(ab′)2 it is possible to achieve therapeutic absorbed doses in microscopic tumor clusters without significant toxicity.
1 March 2004 in Journal of Pain and Symptom Management
The aim of the study was to investigate the clinical and morphological effects of radiotherapy in the treatment of myxoid/round cell liposarcoma (MLS/RCLS). Thirty-three primary and metastatic MLS/RCLS tumours in 15 patients were treated with radiation therapy. Twenty-seven of the 33 tumours were surgically removed after preoperative radiation (34–46 Gy) while six tumours were treated with radiotherapy alone (44–60 Gy). The pretreatment diagnosis was established in all 15 patients based on fine needle aspirates or histological findings. Tumour size was measured by CT or MRI before and after radiotherapy in 30 tumours. Thirteen tumours from 11 patients were genetically characterised before and/or after radiation therapy. Twenty-three of 30 irradiated tumours showed a median reduction in tumour volume of 52% and seven lesions a median progression of 36%. All 27 surgically removed tumours revealed histological features of radiation response. The most striking morphological changes were lipoma-like appearance, paucicellularity and hyalinisation. Twelve of 13 tumours analysed before and/or after radiation therapy showed the FUS-DDIT3 translocation. Radiation therapy of MLS/RCLS induces histopathologic accumulation of mature lipoma-like areas and tumour volume reduction that may facilitate resectability.
The oxygen consumption of isolated, mechanically denuded rat occytes in different stages of meiosis was analyzed by a highly sensitive microspectrophotometric technique. The oocytes were either induced to mature in vivo by LH or matured spontaneously when cultured. In both cases there was a gradual increase in respiration of the oocytes following the onset of morphological nuclear maturation. When oocytes were isolated from preovulatory follicles after LH injection the respiration of maturing oocytes with germinal vesicle breakdown (GVB) was 0.173 ± 0.005 nl O2/h/oocyte (n=25). This is significantly higher than the respiration of dictyate oocytes taken from rats not treated with LH, which was 0.135 ± 0.003 nl O2/h/oocyte (n=38). Oocytes with polar body (PB) consumed 0.206 ± 0.007 nl O2/h/oocyte (n=14) and oocytes recovered from the oviduct after ovulation consumed 0.203 ± 0.004 nl O2/h/oocyte (n=7). For oocytes maturing spontaneously in culture the oxygen consumption was 0.171 ± 0.004 nl O2/h/oocyte (n=33) (oocytes with GVB) and 0.190 ± 0.013 nl O2/h/oocyte (n=4) (oocytes with PB), in both cases a significant increase as compared to control, i.e., not cultured oocytes, which consumed 0.142 ± 0.003 nl O2/h/oocyte (n=18). Neither after LH injection nor after cultivation was the respiration of oocytes still containing germinal vesicle different from control. It is concluded that the resumption of oocyte meiosis is accompanied by an increase in oxygen consumption and that this increase seems to be related to the meiotic process rather than to hormonal stimulation.